NAPHTHYRIDINONDERIVATE ZUR BEHANDLUNG EINER KRANKHEIT ODER STÖRUNG

Patent europeic · EP4436662 · En vigur

Inscripziun en il register

Numer da publicaziun
EP4436662
Numer da la dumonda
EP22817365
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
21-11-2022
Publitgà
02-10-2024
Concedì
17-09-2025
La protecziun finescha il pli tard
20-11-2042
Proxima taxa annuala scadenta
30-11-2026
Classas IPC
A61P 9/00 (2006.01)
C07D 471/04 (2006.01)
A61K 31/4375 (2006.01)
Prioritad
US 202163282492 P 23.11.2021
WO PCT/CN2022/128601 31.10.2022
Dumonda PCT
PCT/IB2022/061218 21.11.2022
Publicaziun PCT
WO2023/094965 01.06.2023
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 29-07-2026

    Midada

    Published in Swissreg on 29.07.2026

  2. 01-12-2025

    Next annual fee due on

    Next annual fee due on
    30.11.2025 → 30.11.2026

    Published in Swissreg on 01.12.2025

  3. 17-09-2025

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 17.09.2025

Partidas

Possessur

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventur

CHEUNG, Atwood Kim

Cambridge, Massachusetts 02139, US

LIU, Donglei

Cambridge, Massachusetts 02139, US

PEUKERT, Stefan

Cambridge, Massachusetts 02139, US

GE, Heng

Changshu, Jiangsu 215537, CN

GAI, Yu

Shanghai 201203, CN

CHANG, Xingjuan

Changshu, Jiangsu 215537, CN

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.